Sensei Biotherapeutics (SNSE) Gets a Buy from Oppenheimer
In a report released on March 28, Francois Brisebois from Oppenheimer maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research ...
Oppenheimer Sticks to Its Buy Rating for Durect (DRRX)
Oppenheimer analyst Francois Brisebois reiterated a Buy rating on Durect (DRRX – Research Report) on March 27 and set a price target of $5.00.
Q4 2024 DURECT Corp Earnings Call
Timothy Papp; Chief Financial Officer; DURECT Corp. James Brown; President, Chief Executive Officer, Director; DURECT Corp. Norman Sussman; Chief Medical Officer; DU ...
DURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitis
Discover DURECT's Q4 2024 earnings insights, progress on larsucosterol's Phase 3 trial for alcohol-associated hepatitis, and strategies to secure funding.